QBSAU - Qu Biologics
Alternative Names: QBSAU SSILatest Information Update: 20 May 2026
At a glance
- Originator Qu Biologics
- Class Antineoplastics; Antirheumatics; Bacterial antigens; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Breast cancer; Malignant melanoma
- Discontinued Bone cancer; Rheumatoid arthritis
Most Recent Events
- 20 May 2026 QBSAU is still in preclinical trials for Malignant melanoma and Breast cancer in Canada (SC) (Qu Biologics pipeline, May 2026)
- 20 May 2026 Discontinued - Preclinical for Bone cancer in Canada (SC) (Qu Biologics pipeline, May 2026)
- 20 May 2026 Discontinued - Preclinical for Rheumatoid arthritis in Canada (SC) (Qu Biologics pipeline, May 2026)